Cargando…

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

BACKGROUND: Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules in tumors are responsible for cetu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Yiqi, Gao, Zhenyue, Hu, Ruxin, Wang, Yuqing, Wang, Yuhong, Su, Zheng, Zhang, Xiaoyue, Yang, Jingxuan, Mei, Mei, Ren, Yu, Li, Min, Zhou, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547513/ https://www.ncbi.nlm.nih.gov/pubmed/34697216 http://dx.doi.org/10.1136/jitc-2021-002699

Ejemplares similares

Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression
por: Lv, Tingting, et al.
Publicado: (2022)

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
por: Yu, Jiongjie, et al.
Publicado: (2023)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

TSH-TSHR axis promotes tumor immune evasion
por: Wu, Zhenghao, et al.
Publicado: (2022)

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
por: Zhang, Biying, et al.
Publicado: (2023)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
por: Sugiyarto, Gessa, et al.
Publicado: (2023)

Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021)

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
por: Collins, Natalie B, et al.
Publicado: (2022)

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
por: Travelli, Cristina, et al.
Publicado: (2023)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
por: Sánchez-Alonso, Santiago, et al.
Publicado: (2020)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
por: Quan, Yibo, et al.
Publicado: (2023)

Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
por: Sun, Mayu, et al.
Publicado: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments
por: Moreno-Vicente, Julia, et al.
Publicado: (2022)

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
por: Fitzgerald, Allison A, et al.
Publicado: (2021)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

New hormone receptor-positive breast cancer mouse cell line mimicking the immune microenvironment of anti-PD-1 resistant mammary carcinoma
por: Perez-Lanzon, Maria, et al.
Publicado: (2023)

Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade
por: Wang, Minglei, et al.
Publicado: (2023)

PD-1(+)CXCR5(−)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma
por: Li, Jiang-Ping, et al.
Publicado: (2021)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
por: Church, Candice, et al.
Publicado: (2022)

Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis
por: Ho, Tuyen Thuy Bich, et al.
Publicado: (2020)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
por: Shen, Yang, et al.
Publicado: (2020)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Kortekaas, Kim E, et al.
Publicado: (2021)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fcba7v9jcordcds3s5263jvd4t